President Donald Trump signed two congressional bills into law on November 3, 2026, extending federal initiatives tied to health research and international religious-freedom policy. The measures cover different areas of government action: one focuses on accelerating the development and availability of therapies for amyotrophic lateral sclerosis, or ALS, while the other renews the agency responsible for monitoring religious-freedom conditions abroad.
According to the White House, Trump signed H.R. 8205 and H.R. 1744 on the same date. H.R. 8205 reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. H.R. 1744 reauthorizes the United States Commission on International Religious Freedom and extends annual appropriations for the commission through fiscal year 2028.
What the ALS law extends
The ALS measure continues a federal program designed to support the development and availability of therapies for people living with amyotrophic lateral sclerosis. ALS is a serious neurodegenerative disease, making the legislation relevant not only to patients and their families but also to researchers and the broader U.S. healthcare system.
By renewing the program through fiscal year 2031, Congress keeps the initiative authorized for the coming years rather than allowing its legal basis to expire at the end of the previous period. In the U.S. legislative system, this type of reauthorization provides continued authority for an existing federal program. It does not, by itself, represent the approval of a particular medicine or announce a new treatment.
The distinction is important for patients and researchers. The law concerns support for the development and availability of therapies, while the safety, effectiveness and authorization of individual treatments remain separate questions. The measure therefore extends the federal framework connected to ALS therapies without changing the announcement into a declaration that a specific treatment is ready for public use.
Renewal of religious-freedom commission
The second law addresses the United States Commission on International Religious Freedom, a federal body whose work involves monitoring religious-freedom conditions in other countries and advising the U.S. government. H.R. 1744 reauthorizes the commission and extends annual appropriations through fiscal year 2028.
This provision gives the commission continued statutory authorization and funding authority for the period established by Congress. Its international focus also connects the measure to U.S. foreign policy and human-rights discussions. The commission’s role is distinct from the ALS program: while the first law concerns medical research and therapy development, the second maintains an institution that examines religious-freedom conditions outside the United States.
For the U.S. government, the renewal preserves a formal channel for gathering information and issuing assessments on religious freedom internationally. For audiences following American diplomacy, the law shows how Congress and the White House can maintain foreign-policy institutions through separate authorization and appropriations measures.
How congressional reauthorization works
Congressional reauthorization is the process used to continue a federal program or agency after an existing authorization period. In this case, lawmakers approved separate bills for the ALS initiative and the religious-freedom commission, and the president’s signature converted them into law.
Authorization and funding are related but not identical. Authorization establishes or renews the legal basis for a program, while appropriations provide the annual funding authority needed for government operations. The White House announcement identifies both elements in H.R. 1744 by referring to the commission’s reauthorization and the extension of annual appropriations through fiscal year 2028.
The two signatures also illustrate the range of federal issues handled through congressional legislation. One measure has a direct public-health focus and is tied to a neurodegenerative disease. The other concerns an institution involved in international monitoring and U.S. human-rights policy. Together, they represent targeted extensions of existing federal activities rather than a single broad policy package.
Trump’s action on November 3 means that both measures received final presidential approval. The ALS program is now extended through fiscal year 2031, while the religious-freedom commission’s authorization and annual appropriations framework continue through fiscal year 2028, according to the White House announcement.
